ArticleCancer research2022

PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer.

Juyeong Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.